Apixaban

Generic Name: Apixaban

Brand Names: Eliquis, Apixaban Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₅N_₅O_₄

CAS Number: 503612-47-3

Unique Ingredient Identifier: 3Z9Y7UWC1J

Background: Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.

Indication: Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.

Associated Conditions: Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism

Associated Therapies: -

Clinical Trials

Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome

Phase 4

Completed

Conditions: Thrombosis
Antiphospholipid Syndrome

Interventions: Drug: Apixaban
Drug: Warfarin

First Posted Date: 2014-11-20

Last Posted Date: 2023-09-28

Lead Sponsor: Scott C. Woller, MD

Target Recruit Count: 48

Registration Number: NCT02295475

Locations: 🇺🇸
The James Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Intermountain Medical Center, Murray, Utah, United States

Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation

Phase 3

Completed

Conditions: Stroke
Atrial Fibrillation
Transient Ischemic Attack

Interventions: Drug: Warfarin
Drug: Apixaban

First Posted Date: 2014-11-05

Last Posted Date: 2021-11-30

Lead Sponsor: University of South Florida

Target Recruit Count: 91

Registration Number: NCT02283294

Locations: 🇺🇸
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸
Bayfront Health St Petersburg, Saint Petersburg, Florida, United States
🇺🇸
University of Louisville, Louisville, Kentucky, United States

and more 2 locations

Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra

Phase 1

Completed

Conditions: Thrombosis

Interventions: Drug: Kcentra
Drug: Apixaban
Drug: Placebo

First Posted Date: 2014-10-21

Last Posted Date: 2016-06-07

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 12

Registration Number: NCT02270918

Locations: 🇺🇸
Thomas Jefferson University Hosptial, Philadelphia, Pennsylvania, United States

Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects

Phase 1

Completed

Conditions: N/A - Healthy Subjects

Interventions: Drug: Apixaban
Drug: Atenolol

First Posted Date: 2014-10-13

Last Posted Date: 2015-08-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 15

Registration Number: NCT02262533

Locations: 🇺🇸
Bms Clinical Research Center, Hamilton, New Jersey, United States

Phase 1 Drug Interaction Study of the Effect of Apixaban on the PK of Digoxin in Healthy Subjects

Phase 1

Completed

Conditions: N/A - Healthy Subjects

Interventions: Drug: Apixaban
Drug: Digoxin

First Posted Date: 2014-10-13

Last Posted Date: 2015-08-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT02262520

Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy

Phase 4

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Vitamin K antagonist
Drug: Apixaban

First Posted Date: 2014-08-28

Last Posted Date: 2017-10-20

Lead Sponsor: Atrial Fibrillation Network

Target Recruit Count: 676

Registration Number: NCT02227550

Locations: 🇳🇱
6 Sites, Different, Netherlands
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸
Texas Cardiac Arrhythmia Research, Austin, Texas, United States

and more 7 locations

Apixaban in Patients With Sickle Cell Disease

Phase 3

Terminated

Conditions: Sickle Cell Disease
Vaso-occlusive Crisis
Reduction in Hospitalizations

Interventions: Drug: Placebo
Drug: Apixaban

First Posted Date: 2014-07-01

Last Posted Date: 2020-03-11

Lead Sponsor: Nirmish Shah

Target Recruit Count: 16

Registration Number: NCT02179177

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Early Post-marketing Study of Eliquis (Apixaban)

Withdrawn

Conditions: Non-valvular Atrial Fibrillation (NVAF)

Interventions: Drug: Apixaban

First Posted Date: 2014-06-03

Last Posted Date: 2016-08-17

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT02153424

Locations: 🇲🇽
Local Institution, Puebla, Mexico

Bioavailability of Apixaban Crushed Tablet

Phase 1

Completed

Conditions: Thrombosis

Interventions: Drug: Apixaban

First Posted Date: 2014-04-01

Last Posted Date: 2016-03-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 69

Registration Number: NCT02101112

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Phase 4

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Parenteral heparin and/or oral Vitamin K antagonist
Drug: Apixaban

First Posted Date: 2014-03-31

Last Posted Date: 2018-05-23

Lead Sponsor: Pfizer

Target Recruit Count: 1500

Registration Number: NCT02100228

Locations: 🇮🇹
Policlinico Universitario Campus Biomedico, Roma, Lazio, Italy
🇷🇴
Brasov Emergency Clinical County Hospital, Brasov, Romania
🇷🇴
Prof.Dr.George I.M. Georgescu Cardiovascular Diseases Institute, Iasi, Romania

and more 161 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy